Merus BV, of Utrecht, the Netherlands, priced a $55 million IPO of 5.5 million common shares at $10 per share and granted underwriters a 30-day option to purchase up to an additional 825,000 common shares. Citigroup Global Markets and Jefferies are acting as joint book-running managers, Guggenheim Securities is acting as lead manager and Wedbush Pacgrow is acting as co-manager. The company raised $80.5 million in a series C round earlier this year to support its bispecific antibody approach in immuno-oncology. Shares began trading on Nasdaq under the ticker symbol MRUS, closing Thursday at $10.04. (See BioWorld Today, Aug. 27, 2015.)
Repligen Corp., of Waltham, Mass. priced an underwritten public offering of $100 million worth of 2.125 percent convertible senior notes due 2021. It also granted the underwriters a 30-day option to purchase up to an additional $15 million worth of notes. The company intends to use net proceeds for working capital and other general corporate purposes, including to fund possible acquisitions or investments, it said. The offering is expected to close on or about May 24. Jefferies is acting as the sole book-running manager, and Janney Montgomery Scott and Craig-Hallum Capital Group are acting as co-managers in the offering.